Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Compass Therapeutics, Inc.

CMPX · Nasdaq · CIK 0001738021 · Healthcare · Biotechnology

INSIDER SIGNAL

56.9 / 100

2 buyers · 4 purchase transaction lines · $96.8K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeLow
RoleStrong
RecencyModerate
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+14.0 / 35
Purchase size+7.4 / 25
Role+18.0 / 20
Recency+7.5 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 2 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ✓ Role scores high · most senior buyer: Chief Accounting Officer
  • ✓ Recent activity · latest purchase 2026-10-01

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Lerner NeilChief Accounting Officer
○●●●
Anderman JonathanGeneral Counsel
○●
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS2
PURCHASE CONCENTRATION51%Largest buyer: Lerner Neil · $49.6K
CLUSTER BUYING · 15D2 insidersPeak activity: 2026-04-29–2026-04-29

Roles in the peak window: Chief Accounting Officer, General Counsel. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

56.9 / 100

Latest recorded score

↓ -0.3 ptsversus the previous recorded snapshot
  1. 57.7
  2. 57.4
  3. 57.3
  4. 57.2
  5. 56.9

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

4Purchases
0Sales
9Other Form 4 lines
13SEC filings · 365 days
BUYING4 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER2 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot detected in parsed evidence

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-51.6%
3M
-56.1%
6M
-80.8%
12M
-74.5%

Volatility & liquidity

Volatility
95.5%
Beta
—
Avg daily value
USD 4.2M

Valuation

Market cap
USD 178.8M
P/E
—

Fundamentals

Profit margin
—
ROE
-33.8%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-07-28 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
40,357,710
Previous report
41,647,512
Avg daily volume
6,449,901
Days to cover
6.3

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-01Lerner NeilPurchase (P)Common Stock20,000USD 0.92USD 18,400SEC filing ↗
2026-09-24Lerner NeilPurchase (P)Common Stock2,500USD 1.14USD 2,850SEC filing ↗
2026-04-29Lerner NeilPurchase (P)Common Stock15,000USD 1.89USD 28,350SEC filing ↗
2026-04-29Anderman JonathanPurchase (P)Common Stock25,000USD 1.89USD 47,250SEC filing ↗
2025-05-27Schuetz Thomas J.Purchase (P)Common Stock10,000USD 2.11USD 21,100SEC filing ↗
2025-04-07Lerner NeilPurchase (P)Common Stock20,000USD 1.42USD 28,400SEC filing ↗
2025-04-07Anderman JonathanPurchase (P)Common Stock20,000USD 1.54USD 30,800SEC filing ↗
2023-03-10Schuetz Thomas J.Purchase (P)Common Stock10,000USD 3.37USD 33,700SEC filing ↗
2023-02-27Schuetz Thomas J.Purchase (P)Common Stock20,000USD 3.98USD 79,600SEC filing ↗
2023-02-15Schuetz Thomas J.Purchase (P)Common Stock20,000USD 3.86USD 77,200SEC filing ↗
2023-01-31Schuetz Thomas J.Purchase (P)Common Stock20,000USD 4.05USD 81,000SEC filing ↗
2023-01-24Schuetz Thomas J.Purchase (P)Common Stock20,000USD 4.19USD 83,800SEC filing ↗
2022-11-08ORBIMED ADVISORS LLC; OrbiMed Capital GP V LLC; OrbiMed Genesis GP LLCPurchase (P)Common Stock402,000USD 3.21USD 1,290,420SEC filing ↗
2022-11-08GORDON CARL LPurchase (P)Common Stock402,000USD 3.21USD 1,290,420SEC filing ↗
2022-09-28Schuetz Thomas J.Purchase (P)Common Stock10,000USD 2.32USD 23,200SEC filing ↗

Form 4 evidence

13 transaction lines in the latest 365-day window; 82 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-01Lerner NeilPurchase (P)Common Stock20,000USD 0.92USD 18,400SEC filing ↗
2026-09-24Lerner NeilPurchase (P)Common Stock2,500USD 1.14USD 2,850SEC filing ↗
2026-04-29Lerner NeilPurchase (P)Common Stock15,000USD 1.89USD 28,350SEC filing ↗
Show recent Form 4 evidence (13 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-01Lerner NeilPurchase (P)Common Stock20,000USD 0.92USD 18,400SEC filing ↗
2026-09-24Lerner NeilPurchase (P)Common Stock2,500USD 1.14USD 2,850SEC filing ↗
2026-04-29Lerner NeilPurchase (P)Common Stock15,000USD 1.89USD 28,350SEC filing ↗
2026-04-29Anderman JonathanPurchase (P)Common Stock25,000USD 1.89USD 47,250SEC filing ↗
2026-04-29Lerner NeilAward / grant (A)Common Stock15,000USD 1.89USD 28,350SEC filing ↗
2026-04-29Anderman JonathanAward / grant (A)Common Stock25,000USD 1.89USD 47,250SEC filing ↗
2026-02-08Schuetz Thomas J.Tax withholding (F)Common Stock36,687USD 6.52USD 239,199SEC filing ↗
2026-01-09Schuetz Thomas J.Tax withholding (F)Common Stock46,777USD 5.35USD 250,257SEC filing ↗
2026-01-02Shin BarryAward / grant (A)Common Stock125,000USD 5.17USD 646,250SEC filing ↗
2026-01-02Schuetz Thomas J.Award / grant (A)Common Stock250,000USD 5.17USD 1,292,500SEC filing ↗
2026-01-02Lerner NeilAward / grant (A)Common Stock62,500USD 5.17USD 323,125SEC filing ↗
2026-01-02Anderman JonathanAward / grant (A)Common Stock150,000USD 5.17USD 775,500SEC filing ↗
2025-11-16Schuetz Thomas J.Tax withholding (F)Common Stock44,025USD 4.83USD 212,641SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerCMPX
CIK0001738021
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history82 transaction lines from 2020-06-19 to 2026-10-01
52 P purchase lines · 7 S sale lines · 23 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.